TNF and infection: Although these drugs are considered relatively safe, the increased risk of serious infection remains an important concern.1–4 Upper respiratory tract infections [URTIs] are among the most common adverse events [AEs] reported in randomised controlled trials of TNF antagonists,5–8 and an increased incidence of URTIs in comparison with placebo has been consistently observed in these studies.7,9,10